Non-ergot dopamine agonists and the risk of heart failure and other adverse cardiovascular reactions in Parkinson's disease

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the risk of heart failure and other adverse cardiovascular reactions in Parkinson disease patients treated with non-ergot dopamine agonists, compared to other anti-Parkinson pharmacological interventions, placebo, or no intervention.